- Telehealth visits
David Balyozian, MD
He | Him | HisPsychiatry (Child and Adolescent Psychiatry)- Telehealth visits
David Balyozian, MD
He | Him | HisPsychiatry (Child and Adolescent Psychiatry)- Telehealth visits
On this page
About me
Dr. David Balyozian is a child and adolescent psychiatrist who cares for patients with mental health conditions. He has particular expertise in treating children younger than 12 and specializes in the care of those with autism, attention-deficit/hyperactivity disorder (ADHD) and aggression.
Balyozian earned his medical degree at UMass Chan Medical School. He completed a residency in pediatrics at the University of California, San Diego and a residency in psychiatry at the University of Southern California. He completed a fellowship in child and adolescent psychiatry at UCSF.
Education & training
Board certification
- Child & Adolescent Psychiatry, American Board of Psych/Neuro Child & Adolescent
- Psychiatry, American Board of Professinal Psychology
Fellowship
- Child and Adolescent Psychiatry, UCSF School of Medicine -GME
Residency
- Psychiatry, University of Southern California GME
- Pediatrics, University of California San Diego
Internship
- Pediatrics, University of California - San Diego
Degree
- MD, University of Massachusetts Medical School
My expertise
Specialties
Clinical Trials query: q=health_gateway_id_ss%3A%28%224384%22%29+AND+status_s%3A%28%22Recruiting%22%29&rows=4&sort=start_date_dt+asc&fq=content_type%3A%22Clinical+Trial%22
Puiblications query: q=health_gateway_id_ss%3A%28%224384%22%29&rows=4&sort=date_published+asc&fq=content_type%3A%22Publication%22
Please check with your health insurance plan regarding coverage for this type of care. Not all providers at UCSF Health are covered by every insurance plan.
For informational purposes only, a link to the federal Centers for Medicare and Medicaid Services (CMS) Open Payments web page is provided here.
The federal Physician Payments Sunshine Act requires that detailed information about payment and other payments of value worth over ten dollars ($10) from manufacturers of drugs, medical devices, and biologics to physicians and teaching hospitals be made available to the public.